VRTX Stock Recent News
VRTX LATEST HEADLINES
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunopro.
The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession. That's a big concern for the market these days as consumers have been keeping discretionary spending to a minimum as high costs have created many affordability issues.
Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.
The Investment Committee give you their stop stocks to watch for the second half.
Toronto, Ontario--(Newsfile Corp. - Le 27 mars/March 2025) - Vortex Energy Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares. As a result, the number of outstanding shares will be reduced to approximately 8,281,056 common shares.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.
Instead of blindly buying during a selloff, Jeremy Mullin offers a four-step plan for 2025 to help investors pinpoint stocks and industries that will lead the next leg higher. Learn how to develop a disciplined strategy to capitalize on the market's abundant opportunities.
Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading day.
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.